Thomas W. Chalberg, PhD is a scientist, entrepreneur, and biotechnology executive. He currently serves as CEO of Genascence Corporation, a clinical-stage gene therapy company developing novel products for osteoarthritis. He is also Founder and Executive Chairman at Irenix, a specialty pharmaceutical company in retina, and Founder/Director at Exhaura, a biotechnology company developing products for glaucoma. Previously, Dr. Chalberg was Founder/CEO of SightGlass Vision, an ophthalmology medical device company (acquired by CooperVision), Chief Operating Officer of Oncorus, Inc. (NASDAQ: ONCR), and Founder and CEO of Avalanche Biotechnologies (NASDAQ: AAVL; later Adverum Biotechnologies, acquired by Eli Lilly). He has also held a number of independent board roles, including Ethris Gmbh, Chameleon Biosciences, CRI Biotech, and DigiSight Technologies. Earlier in his career, Dr. Chalberg worked as a group product manager with Genentech, where he led the strategy team for Lucentis. He began his career as an operations research consultant with ZS Associates in San Mateo, California. Dr. Chalberg has received awards and recognition from the Foundation Fighting Blindness and the World Economic Forum for his contributions to biotechnology. He received his AB in biochemistry from Harvard College, graduating Phi Beta Kappa and magna cum laude, and PhD in genetics from Stanford University School of Medicine, where he was a Howard Hughes Medical Institute Predoctoral Fellow. Tom also earned an MBA from the Haas School of Business at the University of California, Berkeley, focusing on biotechnology and entrepreneurship.